444289
Marimastat
An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor that targets both the substrate binding site and the active-site Zn2+.
别名:
Marimastat, (2S,3R)-N⁴-((1S)-2,2-Dimethyl-1-((methylamino)carbonyl)propyl)-N¹,2-hydroxy-3-(2-methylpropyl)butanediamide, BB-2516
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (NMR)
形狀
solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
white
溶解度
DMSO: 15 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
InChI 密鑰
OCSMOTCMPXTDND-OUAUKWLOSA-N
一般說明
An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他說明
Hansen, H.P., et al. 2002. Int. J. Cancer98, 210.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门